G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 102 filers reported holding G1 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $190 | -47.2% | 83,400 | 0.0% | 0.01% | -48.1% |
| Q1 2024 | $360 | +41.7% | 83,400 | 0.0% | 0.03% | +28.6% |
| Q4 2023 | $254 | +111.7% | 83,400 | 0.0% | 0.02% | +90.9% |
| Q3 2023 | $120 | +39.5% | 83,400 | +142.4% | 0.01% | +57.1% |
| Q2 2023 | $86 | -3.4% | 34,400 | +3.7% | 0.01% | -12.5% |
| Q1 2023 | $89 | -29.4% | 33,160 | +43.2% | 0.01% | -33.3% |
| Q4 2022 | $126 | -100.0% | 23,160 | 0.0% | 0.01% | -58.6% |
| Q3 2022 | $289,000 | +153.5% | 23,160 | 0.0% | 0.03% | +163.6% |
| Q2 2022 | $114,000 | -35.2% | 23,160 | 0.0% | 0.01% | -21.4% |
| Q1 2022 | $176,000 | -25.4% | 23,160 | 0.0% | 0.01% | -22.2% |
| Q4 2021 | $236,000 | -16.3% | 23,160 | +10.3% | 0.02% | -25.0% |
| Q3 2021 | $282,000 | -38.8% | 21,000 | 0.0% | 0.02% | -38.5% |
| Q2 2021 | $461,000 | -8.7% | 21,000 | 0.0% | 0.04% | -17.0% |
| Q1 2021 | $505,000 | +139.3% | 21,000 | +162.5% | 0.05% | +88.0% |
| Q4 2019 | $211,000 | -13.9% | 8,000 | 0.0% | 0.02% | -21.9% |
| Q2 2019 | $245,000 | – | 8,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |